WO2023175090A1 - Formulation pharmaceutique liquide d'oméprazole ou d'ésoméprazole - Google Patents

Formulation pharmaceutique liquide d'oméprazole ou d'ésoméprazole Download PDF

Info

Publication number
WO2023175090A1
WO2023175090A1 PCT/EP2023/056779 EP2023056779W WO2023175090A1 WO 2023175090 A1 WO2023175090 A1 WO 2023175090A1 EP 2023056779 W EP2023056779 W EP 2023056779W WO 2023175090 A1 WO2023175090 A1 WO 2023175090A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
composition
formulation according
agents
combination
Prior art date
Application number
PCT/EP2023/056779
Other languages
English (en)
Inventor
Nadica VANOVA NAKJINOVA
Vlado PETRUSEVSKI
Ana JANEVSKA
Andrew Willis
Original Assignee
Alkaloid Ad Skopje
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkaloid Ad Skopje filed Critical Alkaloid Ad Skopje
Priority to AU2023233849A priority Critical patent/AU2023233849A1/en
Publication of WO2023175090A1 publication Critical patent/WO2023175090A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Definitions

  • the present invention is directed to a two-part pharmaceutical formulation comprising a substituted benzimidazole, more specifically esomeprazole.
  • the present invention also relates to preparations of such pharmaceutical formulations.
  • Proton pump inhibitors are a class of medicaments whose main action is a pronounced and long-lasting reduction of stomach acid production. They have the general structure (I)
  • Esomeprazole is a single enantiomer of omeprazole.
  • Dexlansoprazole is a single enantiomer of lansoprazole.
  • Omeprazole is a substituted benzimidazole, 6-methoxy-2- [[(4- methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1 H-benzimidazole that reduces gastric acid production by irreversibly inhibiting the H + /K + ATPase (proton pump) at the secretory surface of the gastric parietal cells.
  • the formula of omeprazole is a substituted benzimidazole, 6-methoxy-2- [[(4- methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1 H-benzimidazole that reduces gastric acid production by irreversibly inhibiting the H + /K + ATPase (proton pump) at the secretory surface of the gastric parietal cells.
  • the formula of omeprazole is
  • the proton pump is directly responsible for secreting H + ions into the lumen of the stomach.
  • omeprazole regulates the final step of hydrogen ion production in the pathway for gastric acid secretion in the gastrointestinal tracts of mammals.
  • Omeprazole and other proton pump inhibitors are used in the treatment of a number of conditions which require reduction in acid production by proton pump inhibition, such as gastritis, gastroesophageal reflux disease (GERD), dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenum ulceration and Zollinger-Ellison syndrome.
  • GFD gastroesophageal reflux disease
  • dyspepsia peptic ulcer disease
  • laryngopharyngeal reflux gastric and duodenum ulceration
  • Zollinger-Ellison syndrome Zollinger-Ellison syndrome.
  • omeprazole is formulated as tablets or capsules for oral administration.
  • formulations present problems for patients who may be unable and/or unwilling to swallow capsules or tablets. This form is also undesirable for paediatric use.
  • omeprazole is an acid labile compound and therefore, rapidly degrades in acidic conditions such as the environment found in the stomach.
  • Omeprazole is known to degrade with a half-life of less than 10 minutes in an environment having a pH of below 4.0; at pH 6.5, the half-life is 18 hours and at pH 11 , about 300 days.
  • omeprazole as a solid suspension, in which granules of omeprazole are mixed with a suitable carrier.
  • the suspension needs to be prepared immediately before use and it needs a strict control in the way it is prepared. As a result, there is a chance that the medicine may be rendered ineffective if not prepared correctly. Some patients also find the suspension very unpleasant to consume. Since the shelf-life is very short for omeprazole formulated as a suspension, it is also difficult to batch manufacture these.
  • the present invention is related to a pharmaceutical formulation comprising omeprazole, esomeprazole, or other proton pump inhibitors, or a mixture thereof, which provides cost effective means for the treatment of the aforementioned conditions and is convenient to prepare. It also provides alternatives to patients unable and/or unwilling to ingest capsules.
  • the present formulation is stable, easily dissolvable and it allows immediate release and rapid absorption of the therapeutic agent without it being degraded by the stomach acid.
  • US 2009/048322 relates to a drug delivery system, comprising a benzimidazole derivative, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. The formulations appear to be adapted for pulmonary delivery.
  • WO 2003/086392 A2 relates to orally deliverable finely divided self- emulsifiable pharmaceutical compositions that comprise a drug of low water solubility i.e., a cyclooxygenase-2 inhibitory drug, more particularly to such compositions where the drug is in dissolved form, and to processes for preparing such compositions.
  • a drug of low water solubility i.e., a cyclooxygenase-2 inhibitory drug
  • CA 2934538 A1 relates methods of preparing a medical solution comprising a therapeutic agent. It further relates to dry drug compositions (e.g., dry powder compositions) that can be dissolved and/or reconstituted rapidly for delivery to a patient.
  • dry drug compositions e.g., dry powder compositions
  • the present invention addresses problems associated with the prior art.
  • the invention provides a pharmaceutical formulation comprising a first composition being a non-aqueous liquid comprising a substituted benzimidazole and a polar aprotic solvent; and a second composition being an aqueous liquid comprising a base; wherein the first and the second compositions are configured to be combined before use to provide a combined liquid medicament having a pH in the range of between 7.5 to 9.5.
  • the pharmaceutical formulation of the present invention is provided for use as a medicament to treat a condition selected from the group consisting of gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenum ulceration or Zollinger-Ellison syndrome.
  • a kit comprising a first compartment containing a first composition as defined herein; a second compartment containing a second composition as defined herein; wherein the first and second containers are adapted to allow fluid communication between them on actuation to form a combined liquid medicament as defined herein.
  • a method of treatment of a patient in need thereof of a condition selected from the group consisting of gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenum ulceration or Zollinger-Ellison syndrome comprising admixing a first composition as defined herein and a second composition as defined herein and administering the combined liquid medicament to the patient.
  • Figure 1 shows a two-part container suitable for storing the pharmaceutical formulation of the invention.
  • a two-part pharmaceutical formulation comprising a first and a second composition wherein the first composition is a non-aqueous liquid comprising a substituted benzimidazole and a polar aprotic solvent, and the second composition is an aqueous liquid comprising a base, wherein the two compositions are combined to achieve a combined liquid medicament for oral use.
  • the substituted benzimidazole is selected from the group of proton pump inhibitors.
  • the proton pump inhibitor is preferably one of those defined in Formula (I) above, including pharmaceutically acceptable salts, esters and enantiomeric mixtures thereof. More preferably the therapeutic agent is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, dexlansoprazole, timoprazole, picoprazole, pantoprazole, rabeprazole, and tenatoprazole.
  • These proton pump inhibitors may be used singularly or in combination with each other. These inhibitors provide lasting reduction of gastric acid production by blocking the hydrogen/potassium adenosine triphosphate enzyme system (H + /K + ATPase) of the gastric parietal cells.
  • the therapeutic agent is selected from omeprazole, esomeprazole, pantoprazole and pharmaceutically acceptable salts, enantiomers, alkaline salts, enantiomers, hydrates, or derivatives thereof.
  • the therapeutic agent is omeprazole or a pharmaceutically acceptable salt.
  • a pharmaceutically acceptable salt of the therapeutic agent may comprise alkali metal salts such as sodium, lithium and potassium salts.
  • a pharmaceutically acceptable salt of the therapeutic agent may also comprise alkaline earth and transition metal salts such as calcium and magnesium salts. Particularly preferred are metal salts of esomeprazole, particularly esomeprazole sodium.
  • the concentration of the therapeutic agent present in the first composition is between about 10 mg/ml to about 200mg/ml.
  • the amount of the therapeutic agent in the first composition may be between about 50 mg/ml to about 100 mg/ml. More preferably, the therapeutic agent is at a concentration of about 70mg/ml. This therapeutic agent is found to be stable in the polar aprotic solvent at these concentrations.
  • the first composition is present in an amount of from 1 to 5 mL, preferably about 2 mL.
  • the second composition is present in an amount of from 25 to 100 mL, preferably about 68 mL.
  • the therapeutic agent may be present in the first composition in any suitable form, such as in the form of a suspension, liquid, solution, powder, granules, dry powder, dry granules, or microgranules.
  • the therapeutic agent may additionally be provided with a coating, such as, for example, an enteric coating which would be stable from degradation when in contact with an acidic medium, such as present in the stomach, but would break down rapidly at a higher pH, when in the gastrointestinal tract for absorption.
  • the therapeutic agent is provided in the form of a liquid, preferably a solution.
  • polar aprotic solvent refers to a solvent that lacks an acidic proton and is polar.
  • the polar aprotic solvent is at miscible with water.
  • the polar aprotic solvent is a sulphur- containing solvent.
  • the polar aprotic solvent is dimethyl sulfoxide (DMSO).
  • the second composition of the present invention comprises a diluent and a base.
  • the diluent may be any suitable liquid aqueous diluent, for instance, water, or a mixture of one or more solvents comprising water.
  • the diluent is water.
  • the amount of the diluent depends on the final volume of the formulation required depending on the concentration of the therapeutic agent.
  • the second composition of the present invention may comprise one or more pharmaceutical excipients and/or adjuvants. These are preferably selected from one or more of the group consisting of viscosity building agents, dispersing agents, emulsifiers, stabilizers, preservatives, antifoam agents, flavouring agents, antioxidants, sequestering agents and tonicity adjusting agents.
  • Viscosity building agents serve to regulate the viscosity of the formulation and decrease the bitterness of the active pharmaceutical ingredient.
  • the amount of the thickening agents depends on the viscosity of the final formulation and/or the therapeutic agent required.
  • DV2T RV Viscometer is used for apparent viscosity measurement in the present invention.
  • the viscosity of the final pharmaceutical formulation (combined solution) of the present invention may be from about 200 centipose to about 600 centipose.
  • the viscosity of the final formulation is from about 300 centipose to about 400 centipose.
  • the viscosity of the first composition may be from about 150 centipose to about 450 centipose or from about 200 centipose to about 300 centipose.
  • the viscosity of the second composition may be from about 350 centipose to about 650 centipose, or from about 400 centipose to about 550 centipose.
  • the thickening agent may be selected from carageenans, powdered cellulose, sodium alginate, methylcellulose, hydroxyl ethyl cellulose, hydroxyl propyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose I microcrystalline cellulose mixtures, ion-exchange cross-linked polyacrylic polymers, polysaccharides, starches, carbomers, or a mixture thereof.
  • the thickening agent is a combination of polysaccharide and sodium carboxymethylcellulose. Xanthan gum is preferred.
  • Emulsifiers serve to maintain the second composition in the form of a stable emulsion.
  • Emulsifiers are preferably selected from polyglycerol esters, polysorbates, mono- and di-glycerides of fatty acid esters, phosphatidylcholine (lecithin), and polyoxyethylene derivatives of sorbitan fatty acid esters.
  • Preferred emulsifiers have a hydrophilic-lipophilic balance (HLB) of greater than 8 in the case of water-based diluent/second composition, and lower than 8 in the case of emulsion diluent/second composition. Hydrophilic-lipophilic balance (HLB) may be assessed by the method of Davies Proceedings of the International Congress of Surface Activity, 1957, pp.
  • Preferred emulsifiers are selected from polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxylglycerides of sorbitan monooleate, phosphatidylcholine, polyglyceryl-3 oleate and mixtures thereof.
  • Stabilizers are incorporated into the second composition to prevent aggregation.
  • Stabilizers are preferably selected from PVP (povidone), PVA (polyvinyl alcohol), PEG (polyethylene glycol), HPMC (hypromellose), HPC (hydroxypropyl cellulose), HEC (hydroxyethyl cellulose), NaCMC (carboxymethylcellulose sodium), SD (docusate sodium), SLS (sodium lauryl sulphate), PEI (polyehtylene imine), TPGS (D- a - tocopheryl polyethylene glycol succinate), PEG (polyethylene oxide) and PPG (polypropylene oxide), amino acids (preferably Arginine, cysteine and/or glycine), poloxamers and mixtures thereof.
  • Preferred stabilizers are selected from amino acids (preferably Arginine, cysteine and/or glycine), poloxamers and mixtures thereof.
  • Poloxamer 407 is particularly preferred (BASF trade name
  • Preservatives preserve the second composition to prevent decomposition and microbial growth.
  • the preservatives may be quaternary ammonium compounds (such as benzalkonium chloride (BAC), didecyldimethylammonium chloride (DDAC)), parabens, butylated hydroxytoluene, butylated hydroxyanisole, tert-butylhydroquinone EDTA, disodium EDTA or a salt thereof; sugar alcohol such as glycerol and sorbitol; polyoxyethylene 20 sorbitan monooleate such as polysorbate 80, polyoxyethylene 20 sorbitan monolaurate like polysorbate 20; disodium phosphate; or a mixture thereof.
  • BAC benzalkonium chloride
  • DDAC didecyldimethylammonium chloride
  • parabens butylated hydroxytoluene, butylated hydroxyanisole, tert-butylhydroquinone
  • Preferred preservatives are selected from quaternary ammonium compounds, parabens, butylated hydroxytoluene, butylated hydroxyanisole, tert- butylhydroquinone and mixtures thereof.
  • the preservatives may be about 0.01% (w/v) to about 2% (w/v), more preferably, about 0.1% (w/v).
  • the anti-foaming agent prevents the formation of any bubbles or foaming.
  • Suitable antifoaming agents may be selected from silicone based antifoaming agent such as, simethicone or its emulsion or suspension, and non-silicone anti-foaming agents like polypropylene based polyether dispersions, castor oil, fatty alcohol esters, glycerides and a mixture thereof.
  • a preferred antifoam agent is simethicone.
  • the antifoam agent is preferably present in an amount of from 0.05 to 0.5% (w/v).
  • sweetening agents and flavouring agents are used to mask the bitter taste of the active pharmaceutical ingredient and thus, a formulation with good palatability and acceptability is provided.
  • Suitable sweetening agents for use in the present invention are sugars, sugar alcohols, sodium saccharide, aspartame, acesulfame potassium, stevia, sodium cyclamate, propylene glycol, liquorice extract, glycyrrhizin, maple extract and locust bean extract.
  • Suitable flavouring agents may be selected from taste-mask sweetness flavour, sucralose, menthol (mint), lemon, orange, peach, cinnamon, black current, cherry and chocolate.
  • sweetening agents and flavouring agents may be present in an amount from about 1 .0% (w/v) to about 0.01% (w/v). More preferably, these agents may be present in an amount from about 0.25% (w/v), 0.2% (w/v), 0.15% (w/v), or 0.015% (w/v).
  • Suitable antioxidants for use in the second composition are selected from ascorbic acid derivatives, thiol derivatives, sulphites, sodium sulfates, synthetic hindered phenols like propyl gallate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), natural hindered phenols like tocopherols, or a mixture thereof.
  • the antioxidant lends stability to the therapeutic agent and prevents oxidative degradation.
  • the amount of antioxidant in the composition may be from about 0.05% (w/v) to about 0.5% (w/v), preferably from about 0.1% (w/v) to about 0.3% (w/v) of the first composition. However, it is preferred that no antioxidant is present.
  • Tonicity adjusting agents used in this invention is to give the combined formulation an osmolality in the range of from about 1000 to about 3000 mOsmol /kg.
  • the osmolality may be from about 1000 to about 1500 mOsmol /kg or from about 1500 to about 2500 mOsmol /kg or from about 1500 to about 2200 mOsmol/kg.
  • the presence of osmotic agents within this range ensures that the pharmaceutical formulation achieved has acceptable hypertonicity such that the formulation can be consumed in an undiluted form.
  • the osmotic agents may be selected from dextrose, mannitol, sorbitol, glycerol, sodium chloride and sodium sulphate or a combination thereof.
  • the base serves to regulate the pH of the formulation.
  • the base is capable of modifying the pH of the final (i.e. combined first and second composition) formulation to obtain a desired pH that prevents the therapeutic agent form being degraded by the acidic gastric fluids, and is suitable for oral administration.
  • the pH of the final formulation is between 7.5 and 9.5.
  • the pH of the final formulation is between 8 and 9.
  • the pH of the combined solution is between pH 8.5 and 9.
  • the pH of the combined solution is about 9.
  • the base may be selected from alkali metal or alkaline earth metal carbonates or bicarbonates, alkali metal or alkaline earth metal hydroxides, alkali metal or alkaline earth metal oxides, alkali metal or alkaline earth metal phosphates, citrates, acetates and a mixture thereof.
  • the base is potassium bicarbonate.
  • the base ensures that when the first and second compositions are mixed, the combined medicament brought back within the acceptable range, and hence the pH of the combined liquid medicament is consistent and stable on administration.
  • the therapeutic agent used in this invention is preferably sparingly soluble in water at pH 7.
  • the second composition comprises a co-solvents in this invention is to improve the solubility of the active pharmaceutical ingredient in the combined preparation.
  • the solvents and co-solvents may be selected from glycerol, sorbitol, propylene glycol, alcohol, polyethylene glycols, or a mixture thereof.
  • the solvents and co-solvents may be sugar alcohol.
  • the solvents and cosolvents may be present in amount from about 5% (w/v) to about 20% (w/v), more preferably, from about 10% (w/v) to about 15% (w/v).
  • dispersing agents The function of the dispersing agents is to aid sparingly soluble components to dissolve properly.
  • Suitable dispersing agents for use in this invention are glycerol, sorbitol, propylene glycol, polyethylene glycols, alcohol and combinations thereof.
  • the first and the second composition are both provided in the form of a solution.
  • the combined liquid medicament is homogeneous.
  • the first composition and second composition are provided in volumes such that when combined, the volume of combined liquid medicament is acceptable for a several individual oral doses.
  • the volume of combined liquid medicament is between 1 and 150 ml, preferably 20 to 100 ml, more preferably 50 to 90 ml, such as around 70 ml.
  • the volumes of the first and second compositions are selected to provide such a total volume of combined liquid medicament.
  • the volume of combined medicament is suitable to provide from 1 to 50 individual doses, such as between 5 to 20 individual doses. Individual doses comprise from 5 to 50 mg, preferably 10 to 40 mg.
  • the clinician will measure out the appropriate dose of the combined liquid medicament and administer to the patient in need thereof.
  • the present invention provides a kit that comprises the first and second compositions, such that both the compositions are stored separately and are combined to form a combined liquid immediately prior to use.
  • the resulting combined liquid medicament preferably has a pH of from 7.5 to 9.5 and this pH stability is maintained for at least 7 days.
  • the first and second compositions, kept separately, can be stored for at least 12 months and the active pharmaceutical agent maintains its activity for at least 12 months.
  • the kit may comprise a removable barrier between the two compositions.
  • the removable barrier is configured to prevent contact between the two compositions whereby the removal of the removable barrier allows combining of the two compositions immediately before consumption to provide the combined solution.
  • the barrier is a breakable membrane.
  • the removable barrier may be reusable as long as it can separate the two compositions and be removed so as to allow mixing of the two compositions.
  • the removable barrier may be two separate containers for the two compositions having removable openings such as caps or lids.
  • the removable barrier may have a feature of a single container comprising the two compositions separated by the removable barrier.
  • the removable barrier is made of plastic or glass. More preferably, the removable barrier is made of amber high-density polyethylene.
  • the pharmaceutical formulation of the present invention is provided for use in the treatment of a number of conditions such as gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenum ulceration, and Zollinger- Ellison syndrome whereby the condition is treated by proton pump inhibition.
  • the pharmaceutical formulation of the present invention is suitable for adults and children.
  • the clinician or patient admixes the first and second compositions to form a combined liquid, which is then directly orally administered to the patient.
  • the formulations and kits of the invention combine a long shelf-life with minimal degradation of the active substance, together with a convenient and palatable dosage form for administration.
  • a suitable dual - chamber multi dose pack for storage and mixture of the compositions of the invention comprises:
  • Cap (1 ) over the first chamber comprising a means to exert pressure onto the plunger (3) so as to partially rupture the breakable polymeric membrane (4) of the plug and deliver the solution into the container (6) with the second liquid composition, diluent for the esomeprazole solution in amount of 68 mL.
  • the tamper evident tear band (2) ensures the overall integrity of the product until the time of the administration.
  • a first chamber composed comprising:
  • Plunger (3) adapted to fit into a plug (4) having a top flat surface, containing a first composition esomeprazole oral solution in amount of 2 ml.
  • Second chamber comprising:
  • container (6) the two liquid compositions are mixed at the time of the administration.
  • Example 1 (emulsion) 20 mg/10 ml, 70 ml:
  • the potassium hydrogen carbonate, sodium carbonate, sucralose, , polysorbate 80, and simethicone emulsion were dissolved in water, and heated to 65 °C (hydrophilic phase).
  • the phosphatidylcholine, methylparaben, and butylated hydroxytoluene were dissolved in heated olive oil to 75 °C (lipophilic phase), Carboxymethylcellulose sodium is dispersed afterwards.
  • the hydrophilic phase was dispersed in the lipophilic phase under high speed homogenization at 1500-4000 rpm for 15 minutes.
  • flavours were added and mixed for additional 1 hour. A stable emulsion was obtained.
  • the two compositions were stored in a dual chamber system, where the API in DMSO was contained in the first chamber (made of HDPE / PE / PP) and 68 ml of diluent in the second chamber.
  • the second chamber was made of HDPE or PET plastic with a volume of 100 ml.
  • the two compositions were combined, and shaken.
  • the appropriate volume of combined formulation is measured out with e.g. a syringe or dosing spoon, and administered to a patient in need thereof.
  • Example 2 (emulsion) 20 mg/10 ml, 70 ml:
  • the emulsion was prepared by a similar method to Example 1 - potassium hydrogen carbonate, sodium carbonate, sucralose, carboxymethyl cellulose sodium, PEG 40 hydrogenated castor oil, and simethicone emulsion formed the hydrophilic phase, and phosphatidylcholine, polyglyceryl-3 oleate, methylparaben and butylated hydroxytoluene formed the lipophilic phase.
  • Example 3 (water-based solution) 20 mg/10 ml, 70 ml:
  • the potassium hydrogen carbonate and sodium carbonate salts were dissolved 2/3 of the water. Subsequently, the benzalkonium chloride was dissolved with a mixing time of 15 minutes in a propeller mixer at 80 rpm.
  • cyclodextrin and sweetener were dissolved sequentially with in-between mixing times of 15 minutes.
  • the polymer was added at a higher stirrer speed (at least 100 rpm) in a propeller mixer in 3 portions.
  • the polymer was hydrated for 1 hour, and after full hydration the remaining flavours were added and mixed for an additional 30 minutes with propeller mixer operating at a minimum of 100 rpm.
  • the two compositions were stored in a dual chamber system, where the API in DMSO was contained in the first chamber (made of HDPE / PE / PP) and 68 ml of diluent in the second chamber (aqueous solution).
  • the second chamber was made of HDPE plastic, PET or (preferably) amber glass with volume of 120-130 ml.
  • the appropriate volume of combined formulation is measured out with e.g. a syringe or dosing cup and administered to a patient in need thereof.
  • Example 4 water-based solution 20 mg/10 ml, 70 ml:
  • Example 5 (water based solution) 20 mg/10 ml, 70 ml: First chamber:
  • Example 6 (water based solution) 20 mg/10 ml, 70 ml First chamber:
  • RRT Relative retention time
  • Example 2 The aqueous emulsion and the combined medicament of Example 2 was judged as palatable by a cohort of volunteers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle formulation à deux composants d'un principe actif, en particulier un inhibiteur de pompe à protons. La formulation à deux composants est stable pendant des périodes prolongées lors du stockage, et les composants sont combinés pour donner une formulation qui est appropriée pour une administration orale, ayant une bonne palatabilité et une bonne efficacité.
PCT/EP2023/056779 2022-03-18 2023-03-16 Formulation pharmaceutique liquide d'oméprazole ou d'ésoméprazole WO2023175090A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023233849A AU2023233849A1 (en) 2022-03-18 2023-03-16 Liquid pharmaceutical formulation of omeprazole or esomeprazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2203764.2 2022-03-18
GB2203764.2A GB2616663A (en) 2022-03-18 2022-03-18 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
WO2023175090A1 true WO2023175090A1 (fr) 2023-09-21

Family

ID=81344945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/056779 WO2023175090A1 (fr) 2022-03-18 2023-03-16 Formulation pharmaceutique liquide d'oméprazole ou d'ésoméprazole

Country Status (4)

Country Link
AR (1) AR128808A1 (fr)
AU (1) AU2023233849A1 (fr)
GB (1) GB2616663A (fr)
WO (1) WO2023175090A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086392A2 (fr) 2002-04-09 2003-10-23 Pharmacia Corporation Procede pour preparer une composition pharmaceutique finement auto-emulsifiable
KR20040099265A (ko) * 2002-01-19 2004-11-26 더 큐레이터스 오브 더 유니버시티 오브 미주리 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
US20090048322A1 (en) 2003-08-13 2009-02-19 Diana Shu-Lian Chow Parenteral and oral formulations of benzimidazoles
US8530500B2 (en) * 2009-07-20 2013-09-10 Vetegen, Llc Stable pharmaceutical omeprazole formulation for oral administration
CN103288801A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种高纯度埃索美拉唑钠的制备方法
CA2934538A1 (fr) 2013-12-18 2015-06-25 Windgap Medical, Inc. Systeme et procede de melange et de liberation d'un medicament
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
CN112661744A (zh) * 2020-12-28 2021-04-16 北京悦康科创医药科技股份有限公司 一种艾司奥美拉唑钠的纯化方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040099265A (ko) * 2002-01-19 2004-11-26 더 큐레이터스 오브 더 유니버시티 오브 미주리 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
WO2003086392A2 (fr) 2002-04-09 2003-10-23 Pharmacia Corporation Procede pour preparer une composition pharmaceutique finement auto-emulsifiable
US20090048322A1 (en) 2003-08-13 2009-02-19 Diana Shu-Lian Chow Parenteral and oral formulations of benzimidazoles
US8530500B2 (en) * 2009-07-20 2013-09-10 Vetegen, Llc Stable pharmaceutical omeprazole formulation for oral administration
CN103288801A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种高纯度埃索美拉唑钠的制备方法
CA2934538A1 (fr) 2013-12-18 2015-06-25 Windgap Medical, Inc. Systeme et procede de melange et de liberation d'un medicament
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
CN112661744A (zh) * 2020-12-28 2021-04-16 北京悦康科创医药科技股份有限公司 一种艾司奥美拉唑钠的纯化方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIES, PROCEEDINGS OF THE INTERNATIONAL CONGRESS OF SURFACE ACTIVITY, 1957, pages 426 - 38

Also Published As

Publication number Publication date
GB202203764D0 (en) 2022-05-04
AU2023233849A1 (en) 2024-10-10
GB2616663A (en) 2023-09-20
AR128808A1 (es) 2024-06-12

Similar Documents

Publication Publication Date Title
US10238640B2 (en) Pharmaceutical suspension composition
KR101360526B1 (ko) 개선된 약력학적 특성을 갖는 약물 제형
US20240122846A1 (en) Pharmaceutical composition comprising an androgen receptor inhibitor
IL205352A (en) Pharmaceutical preparations containing carbysmate aqueous preparations
CN114761002A (zh) 用于奥美拉唑混悬剂的组合物和试剂盒
US11911473B2 (en) Compositions and kits for omeprazole suspension
US12083222B2 (en) Chemotherapeutic pharmaceutical suspension for oral dosage
ES2968899T3 (es) Formulación de la solución oral
US20230172918A1 (en) Pharmaceutical formulation
US20060040991A1 (en) Pharmaceutical presentation form for oral administration of a poorly soluble active compound, process for its preparation and kit
AU2023233849A1 (en) Liquid pharmaceutical formulation of omeprazole or esomeprazole
BRPI0613139A2 (pt) formulação farmacêutica do inibidor de tubulina indibulina para administração oral com aperfeiçoadas propriedades fármaco-cinéticas, e processo para sua fabricação
WO2019162756A2 (fr) Compositions pharmaceutiques liquides de médicaments anticancéreux
ES2973984T3 (es) Granulado multiparticulado que comprende insulina
EP3968955A1 (fr) Solution pharmaceutique orale liquide d'ivacaftor
EA047754B1 (ru) Фармацевтическая композиция
CN111202721A (zh) 含有昂丹司琼或其盐的口腔崩解型膜制剂及其制备方法
ES2974364T3 (es) Formulación de suspensión pediátrica
US20240058306A1 (en) Novel oral liquid compositions of enzalutamide and method of manufacturing thereof
US20240307360A1 (en) Oral dispersible film of mitragynine
TR202005122A2 (tr) Montelukast oral çözelti formülasyonu.
JP2011504162A (ja) 経口投与用チプラナビルの自己乳化型製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23711481

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 202491875

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 16591

Country of ref document: GE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024018237

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: AU2023233849

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023233849

Country of ref document: AU

Date of ref document: 20230316

Kind code of ref document: A